D Daiichi Sankyo
Updates & Highlights
TipRanks · 8 days ago
Daiichi Sankyo Company (4568N) Q1 2024 Earnings Report - Results, Call & Slides
TipRanks · 9 days ago
Daiichi Sankyo Company (4568N) Q4 2025 Earnings Report - Results, Call & Slides
The Pharma Letter · 13 days ago
From persistence to precision: how Daiichi Sankyo is evolving its R&D strategy in oncology
Recent Openings
View all 1 jobs arrow_forwardData Scientist - Pharmaceutical Development and Manufacturing (m/f/d)
location_on Pfaffenhofen an der Ilm, BY, DE
All Jobs
Data Scientist - Pharmaceutical Development and Manufacturing (m/f/d)
location_on Pfaffenhofen an der Ilm, BY, DE
Culture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Daiichi Sankyo?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentDaiichi Sankyo Company (4568N) Q1 2024 Earnings Report - Results, Call & Slides
Daiichi Sankyo Company (4568N) Q1 2024 Earnings Report - Results, Call & Slides
TipRanks · 8 days ago
Daiichi Sankyo Company (4568N) Q4 2025 Earnings Report - Results, Call & Slides
Daiichi Sankyo Company (4568N) Q4 2025 Earnings Report - Results, Call & Slides
TipRanks · 9 days ago
From persistence to precision: how Daiichi Sankyo is evolving its R&D strategy in oncology
From persistence to precision: how Daiichi Sankyo is evolving its R&D strategy in oncology
The Pharma Letter · 13 days ago
AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer
AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer
MSN · 14 days ago
Canon Stock, Toyota And Daiichi Sankyo For Dividend Income In Japan
Canon Stock, Toyota And Daiichi Sankyo For Dividend Income In Japan
simplywall.st · 21 days ago
Daiichi Sankyo Company (4568) Q4 2026 earnings summary
Daiichi Sankyo Company (4568) Q4 2026 earnings summary
Quartr · 25 days ago
Daiichi Sankyo (TSE:4568) Is Up 5.5% After EU Pan-Tumor Enhertu Approval And ADC Milestones
Daiichi Sankyo (TSE:4568) Is Up 5.5% After EU Pan-Tumor Enhertu Approval And ADC Milestones
simplywall.st · 26 days ago
Audit Review Item 26/03: Daiichi Sankyo (Revised Report) – Provision for Loss Compensation Related to Manufacturing Outsourcing of ADC Products
Audit Review Item 26/03: Daiichi Sankyo (Revised Report) – Provision for Loss Compensation Related to Manufacturing Outsourcing of ADC Products
Moomoo · about 1 month ago
Daiichi Sankyo: Not Exciting Enough For This Market, Apparently (OTCMKTS:DSKYF)
Daiichi Sankyo: Not Exciting Enough For This Market, Apparently (OTCMKTS:DSKYF)
Seeking Alpha · about 1 month ago
Enterprise value to EBITDA forward of Daiichi Sankyo Company, Limited – TSE:4568
Enterprise value to EBITDA forward of Daiichi Sankyo Company, Limited – TSE:4568
TradingView · about 1 month ago
Building an oncology powerhouse: Daiichi Sankyo's next phase of growth in Europe and Canada
Building an oncology powerhouse: Daiichi Sankyo's next phase of growth in Europe and Canada
The Pharma Letter · about 1 month ago
Daiichi Sankyo : Consolidated Financial Statements and Independent Auditor's Report for FY2025PDF
Daiichi Sankyo : Consolidated Financial Statements and Independent Auditor's Report for FY2025PDF
marketscreener.com · about 1 month ago
Daiichi Sankyo Secures 200 Billion Yen Loan
Daiichi Sankyo Secures 200 Billion Yen Loan
marketscreener.com · about 2 months ago
Daiichi Sankyo Company, Limited Concludes Money Loan Agreement with Financial Covenants
Daiichi Sankyo Company, Limited Concludes Money Loan Agreement with Financial Covenants
marketscreener.com · about 2 months ago
Daiichi Sankyo’s Vanflyta approved in China
Daiichi Sankyo’s Vanflyta approved in China
The Pharma Letter · about 2 months ago
Daiichi Sankyo Co Ltd - Notice Regarding Conclusion Of A Money Loan Agreement With Financial Covenants
Daiichi Sankyo Co Ltd - Notice Regarding Conclusion Of A Money Loan Agreement With Financial Covenants
TradingView · about 2 months ago
‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game
‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game
Fierce Biotech · about 2 months ago
Daiichi Sankyo : Vanflyta® Approved in China as First and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3-ITD Positive AML
Daiichi Sankyo : Vanflyta® Approved in China as First and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3-ITD Positive AML
marketscreener.com · about 2 months ago
Daiichi Sankyo's trademark win falls short on online-monitoring costs
Daiichi Sankyo's trademark win falls short on online-monitoring costs
MLex · about 2 months ago
How Daiichi Sankyo aims to become a top five oncology player by 2035
How Daiichi Sankyo aims to become a top five oncology player by 2035
Labiotech.eu · about 2 months ago